

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Valerio et al.

Serial No.: To be assigned

Filed: July 10, 2001

For: METHOD AND MEANS FOR TARGETED GENE DELIVERY

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 3837.1US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL 740532253 US

Date of Deposit with USPS: July 10, 2001

Person making Deposit: Jared Turner

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

U.S. Patent Documents

#6,033,908 3/7/00 Bout et al. #6,040,174 3/21/00 Imler et al. #FR2649119 1/4/91 France #EP0496074 7/29/92 Europe #WO/9222332 12/23/92 WO #WO/9309221 5/13/93 WO #WO/9416734 8/4/94 WO #WO/9412626 6/9/94	У
#6,040,174 3/21/00 Imler et de Foreign Patent Documents #FR2649119 1/4/91 France #EP0496074 7/29/92 Europe #WO/9222332 12/23/92 WO #WO/9309221 5/13/93 WO #WO/9416734 8/4/94 WO #WO/9412626 6/9/94 WO	al.
#FR2649119 1/4/91 France #EP0496074 7/29/92 Europe #WO/9222332 12/23/92 WO #WO/9309221 5/13/93 WO #WO/9416734 8/4/94 WO #WO/9412626 6/9/94	al.
#FR2649119 1/4/91 Europe #EP0496074 7/29/92 Europe #WO/9222332 12/23/92 WO #WO/9309221 5/13/93 WO #WO/9416734 8/4/94 WO #WO/9412626 6/9/94	
#EP0496074 7/29/92 Europe #W0/9222332 12/23/92 W0 #W0/9309221 5/13/93 W0 #W0/9416734 8/4/94 W0 #W0/9412626 6/9/94	e
#WO/9222332 12/23/92 WO #WO/9309221 5/13/93 WO #WO/9416734 8/4/94 WO #WO/9412626 6/9/94 WO	e
#WO/9309221 5/13/93 WO #WO/9416734 8/4/94 WO #WO/9412626 6/9/94 WO	
#WO/9416734 8/4/94 WO #WO/9412626 6/9/94 WO	
#WO/9412626 6/9/94 WO	١
WO)
#WO/9526412 10/5/95 WO)
#WO/9700326 1/3/97 PCT	ſ

Other Documents

#Boado, R.J. (1995) Adv. Drug Deliv. Rev., 15:73-107.

#Curiel et al. (1994) Virology, 198:577-585.

#Etienne-Julian et al. (1992) J. Gen Virol., (1992) 73: 3251-3255.

#Friedmann, T. "Overcoming the obstacles to gene therapy." Sci. Am. June 1997 pp. 96-101.

#Marin et al. (1994) Gene Therapy, 1(2):s15.

#Nilson et al. (1994) Gene Therapy, 1(2):s17

#Orkin, et al. "Report and recommendations of the panel to assess the NIH investment in research on gene therapy," 12/95.

#Roux et al. (1989) Proc. Natl. Acad. Sci., 86:9079-9083.

#Russell et al. (1993) Nucleic Acids Research, 21(5):1081-1085.

#Truong et al. (1993) Proc. Intern. Symp. Control. Release Bioact. Mater., 20: 474-475.

#Verma et al. "Gene therapy - promises, problems and prospects. (9/97) Nature 389:239-242.

#Zatloukal et al. (1993) J. Cell Biochem., 17(d):129.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/000,133

For: METHOD AND MEANS FOR TARGETED GENE DELIVERY which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, applicant hereby identifies the following listed copending applications naming the same inventors:

Serial No.: 08/820,479

Filed: 3/18/1997

For: METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING

PRIMATE BONE MARROW CELLS

Serial No.: 09/298,745

Filed: 4/23/1999

For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS TO

BE USED IN GENE THERAPY

Serial No.: 09/326,032

Filed: 6/4/1999

For: GENETIC MODIFICATION OF PRIMATE HEMOPOIETIC REPOPULATING

STEM CELLS

Serial No.: 09/333,820

Filed: 6/15/1999

For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS TO

BE USED IN GENE THERAPY

Serial No.: 09/381,716

Filed: 1/4/2000

For: METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING

PRIMATE BONE MARROW CELLS

Serial No.: 09/502,624

Filed: 2/11/2000

For: VECTORS AND METHODS FOR PROVIDING CELLS WITH ADDITIONAL NUCLEIC ACID MATERIAL INTEGRATED IN THE GENOME OF SAID CELLS

Serial No.: 09/506,548

Filed: 2/16/2000

For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS TO

BE USED IN GENE THERAPY

Serial No.: 09/599,488

Filed: 6/23/2000

For: ADENO-ASSOCIATED VIRUS AND ADENOVIRUS CHIMERIC

RECOMBINANT VIRUSES USEFUL FOR THE INTEGRATION OF FOREIGN GENETIC INFORMATION INTO CHROMOSOMAL DNA OF TARGET CELLS

Applicants offer to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. 1.17(p) is required.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041 Attorney for Applicants

TRASKBRITT, PC

P. O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: (801) 532-1922

Date: July 10, 2001

ACT/le/bv

Enclosures:

Form PTO-1449

N:\2578\3837.1\ids.wpd

dr s Ns								Shed	et 1 of 2	
Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION					Docket Number (Opti	Application To be assi	0 T Q			
					Applicant Valerio et al.					
(Use several sheets if necessary)				Filing Date July 10, 2001 Group Art Unit To be assigned			<u>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</u>			
			U.S. 1	PATENT	DOCUMENTS				S.	
EXAMINER INITIAL		UMENT MBER	DATE		NAME	CLASS			FILING DATE IF APPROPRIATE	
	#6,0	33,908	3/7/00		Bout et al.	<u> </u>		ļ		
	#6,040,174		3/21/00		Imler <i>et al</i> .		ļ			
			FOREIG	N PATE	T DOCUMENTS	S				
	DOCUM	MENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	YES	slation NO	
					F			120		
		2649119_	1/4/91		France	+				
		0496074	7/29/92		Europe WO			<u> </u>		
	1"	/9222332	12/23/92	<u> </u>	wo					
)/9309221)/0416734	5/13/93 8/4/94		wo					
)/9416734)/9412626	6/9/94		wo					
)/952641 <u>2</u>	10/5/95		wo					
		0/9700326	1/3/97		PCT			<u> </u>		
	,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		THER DO	CUMENTS	(Includin	g Author, Title, D	ate, Pertinent	Pages, Etc.)	
#Boado, R.J. (1995) Adv. Drug Deliv. Rev., 15:73-107.										
	_	#Curiel et al. (1994) Virology, 198:577-585.								
		#Etienne-Julian <i>et al.</i> (1992) <u>J. Gen Virol.</u> , (1992) <u>73</u> : 3251-3255.								
	#Friedmann, T. "Overcoming the obstacles to gene therapy." <u>Sci. Am.</u> June 1997 pp. 96-									
			al. (1994) <u>Ger</u>	ne Therapy	, <u>1(2</u>):s15.					

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

DATE CONSIDERED

(2-92)

EXAMINER

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/000,133 Filed: February 24, 1998

For: METHOD AND MEANS FOR TARGETED GENE DELIVERY which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

Sheet 2 of 2 **Application Number Docket Number (Optional)** Form PTO-1449 To be assigned 3837.1US INFORMATION DISCLOSURE CITATION Applicant Valerio et al. IN AN APPLICATION Filing Date July 10, 2001 Group Art Unit To be (Use several sheets if necessary) assigned U.S. PATENT DOCUMENTS FILING DATE DOCUMENT CLASS SUBCLASS **EXAMINER** NAME IF APPROPRIATE DATE NUMBER INITIAL FOREIGN PATENT DOCUMENTS Translation DOCUMENT NUMBER CLASS SUBCLASS COUNTRY DATE NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) #Nilson et al. (1994) Gene Therapy, 1(2):s17 #Orkin, et al. "Report and recommendations of the panel to assess the NIH investment in research on gene therapy," 12/95, #Roux et al. (1989) Proc. Natl. Acad. Sci., 86:9079-9083. #Russell et al. (1993) Nucleic Acids Research, 21(5):1081-1085. #Truong et al. (1993) Proc. Intern. Symp. Control. Release Bioact. Mater., 20: 474-475. #Verma et al. "Gene therapy - promises, problems and prospects. (9/97) Nature 389:239-

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

#Zatloukal et al. (1993) J. Cell Biochem., 17(d):129.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE (2-92)#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

DATE CONSIDERED

Serial No.: 09/000,133 Filed: February 24, 1998

EXAMINER

For: METHOD AND MEANS FOR TARGETED GENE DELIVERY which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.